Fig. 2
From: Increased vision impairment reports linked to semaglutide: analysis of FDA adverse event data
The observed association between semaglutide and higher risk for visual impairment also holds for individual GLP-1 receptor agonists. Analysis of FAERS reports of visual impairment in filtered reports with obesity or T2D as main indication for semaglutide and Comparator Substance (monotherapy). Numbers of reports are displayed in the graph as: report for visual impairment/total number of reports, except for semaglutide (n = 417/11,558). Lixisenatide was excluded due to too low case numbers (see Additional file 1: Table S5 for number of reports). rORs were calculated with 95% CI and corresponding p-value (with Yates’ correction). Abbreviations: CI: confidence interval, FAERS: Food and Drug Administration (FDA) adverse event reporting system, rOR: reporting odds ratio, T2D: type 2 diabetes